ProCE Banner Activity


Expert Viewpoints in Myelofibrosis: Advancing Treatment Strategies With Next-Generation Therapeutics

Text Module

In this text activity, Abdulraheem Yacoub, MD, provides expert commentary on recent advances in the treatment of myelofibrosis and discusses emerging investigational strategies.

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: February 07, 2024

Expiration: February 06, 2025



Abdulraheem Yacoub

Abdulraheem Yacoub, MD

The Division of Hematologic Malignancies and Cellular Therapeutics
University of Kansas Medical Center
The University of Kansas Health System
Westwood, Kansas

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by an educational grant AbbVie Inc.

AbbVie Inc.

Target Audience

This activity has been designed to meet the educational needs of hematologists/oncologists and other healthcare professionals involved in managing patients with myelofibrosis.

Program Learning Goal

The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with Myelofibrosis.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Integrate available therapies into an optimal first-line treatment strategy for patients with MF, considering risk stratification, molecular features, cytogenetics, and symptom burden

  • Design evidence-based second-line treatment approaches for patients with MF who are relapsed, refractory, or intolerant to prior JAKi therapy

  • Summarize new data on emerging agents to facilitate clinically appropriate early adoption as approvals change practice


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Abdulraheem Yacoub, MD

The Division of Hematologic Malignancies and Cellular Therapeutics
University of Kansas Medical Center
The University of Kansas Health System
Westwood, Kansas

Abdulraheem Yacoub, MD: consultant/advisor/speaker: AbbVie, Acceleron, Apellis, Blueprint Medicine, CTI Pharma, Gilead, GlaxoSmithKline, Incyte, Karyopharm Therapeutics, Notable Labs, Novartis, Pfizer, PharmaEssentia, Protagonist, Servier.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, learners must follow these steps during the period from February 07, 2024, through February 06, 2025:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.


The program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.